Advertisement
Advertisement

VYNE

VYNE logo

VYNE Therapeutics Inc

2.43
USD
-0.21
-7.96%
Dec 18, 15:59 UTC -5
Closed
...

VYNE Therapeutics Inc Profile

About

VYNE Therapeutics Inc. focuses on developing and commercializing therapeutics for dermatology. The company's product pipeline consist FMX103 and FCD105 which are in clinical stage. VYNE Therapeutics Inc., formerly known as Menlo Therapeutics Inc., is based in Bridgewater, New Jersey.

Info & Links

CEO

David Domzalski

Headquarters

685 ROUTE 202/206, SUITE 301
BRIDGEWATER, NJ 08807, UNITED STATES

Auditor

Baker Tilly US, LLP

Share holders

9

Employees

10

VYNE Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

35.84M

Enterprise Value

19.52M

Enterprise Value/EBITDA(ttm)

-0.49

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

76.60

Price to Book(mrq)

0.59

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-6885.40%

Profit Margin(ttm)

-7329.06%

Return on Equity(ttm)

-43.73%

Return on Invested Capital(ttm)

-46.10%

Return on Assets(ttm)

-38.55%

Income Statement

Revenue(ttm)

493.00K

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

493.00K

EBITDA(ttm)3

-39.60M

Net Income Available to Common(ttm)

-34.00M

Diluted EPS(ttm)

-0.86

Share Statistics

Beta (5Y Monthly)

1.37

52-Week Change

-28.11%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

14.75M

Dividend Yield

0.00%

Float4

14.04M

% Held by Insiders

4.80%

% Held by Institutions

83.78%

Balance Sheet

Total Cash(mrq)

70.23M

Total Cash Per Share(mrq)

4.76

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.81%

Quick Ratio(mrq)

5.81%

Book Value Per Share(mrq)

4.31

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.59

Free Cash Flow(ytd)

-24.97M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement